IC-MPGN Terminated Phase 2 Trials for Danicopan (DB15401)

IndicationStatusPhase
DBCOND0106988 (IC-MPGN)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03459443A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471Treatment